Is an NCD the Right Move for Your Technology? Lessons from CMS’s Final Decision on Renal Denervation
Published on: 29/10/2025
Learn when to pursue a National Coverage Determination (NCD) and what CMS’s renal denervation decision means for MedTech reimbursement and evidence strategy.
Payer CoverageEvidence PlanningCommercialization
Do QALYs Matter in the U.S.?
Published on: 11/03/2025
QALYs are essential in Europe—but not in the U.S. Here's what really drives MedTech coverage decisions and how to pivot.
Evidence Planning
Payer Policy Is Poised to Unlock the Full Potential of AI in MedTech in 2025
Published on: 17/12/2024
U.S. payers are evolving fast. Here’s how AI-driven MedTech innovators can lead—not wait—for reimbursement models.
Payer Coverage
Medicare Proposes to Approve 80% of Transitional Pass Through Applications for Novel Tech in 2025
Published on: 25/08/2024
CMS is signaling support for innovation. Here's what this policy shift could mean for your device.
Coding and Payment
